Abstract

Objective: The objective of this paper is to report the importance of ophthalmic pharmacovigilance in AREDS macular formulations due to the potential toxicity of these macular vitamins with minimal benefit for patients with advanced exudative macular degeneration. Background: Age Related Eye Disease Studies macular formulations are currently treated as nutritional supplements and as such, do not undergo the required evaluation process for toxicity as pharmacologic agents. However, they more closely resemble a pharmacologic agent rather than a true nutritional supplement. Results: Macular formations have minimal benefit for patients with advanced exudative age-related macular degeneration and contain unsafe doses of substances like beta-carotene and zinc, which have the potential to cause cancer, Alzheimer’s disease, and worsen macular degeneration. This potential for toxicity necessitates pharmacovigilance for macular supplements to prevent exposure to harmful substances for negligible gain. Conclusion: These supplements should be replaced with other compounds that have both macular protective properties and an excellent safety profile such as Meso-Zeaxanthin, lutein and zeaxanthin.

Highlights

  • Macular formulations to prevent development of age-related eye diseases, such as exudative macular degeneration, are not considered pharmacologic intervention by many regulatory bodies

  • The potential for toxicity can be a reason a pharmacologic agent does not progress to later stages of clinical trials

  • If a pharmacologic agent demonstrates the potential for adverse toxicity in the course of postapproval surveillance, black box warnings are usually placed to warn patients of the potential side effects

Read more

Summary

Background

Age Related Eye Disease Studies macular formulations are currently treated as nutritional supplements and as such, do not undergo the required evaluation process for toxicity as pharmacologic agents. They more closely resemble a pharmacologic agent rather than a true nutritional supplement

Results
Introduction
Conclusion
Arch Ophthalmol 119
35. Ophthalmology 120
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.